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INTRODUCTION
Current 5-year survival rates for people treated for Hodgkin lymphoma (HL) in childhood exceed 90%. 1, 2 Approximately 31,500 childhood HL survivors live in the United
States, and this population increases annually. 3 Long-term HL survivors commonly experience treatment-related morbidity that impairs thyroid, pulmonary, gonadal, cerebrovascular and cardiovascular (CV) function. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] In addition, their curative therapy has been linked to an excess risk of developing second malignant neoplasms (SMN). [14] [15] [16] [17] [18] [19] [20] [21] These late treatment sequelae can negatively impact survivor's health and predispose to premature death.
22-25
Despite extensive characterization of mortality in HL survivors, the literature contains some important limitations. Prior study populations have mixed survivors of adult and childhood HL. 25, 26 Additionally, studies have included multiple childhood cancer diagnoses, 27 or reported on few mortality events, 10, 23 and had median follow-up time less than 20 years from diagnosis.
Finally, studies have lacked detailed cancer treatment data to establish risk models for mortality. 10, 23, 25, 26 Specifically, neither the Childhood Cancer Survivor Study (CCSS) nor any other study of childhood HL survivors have evaluated the association between mortality, patient characteristics, treatment, and treatment mediated co-morbid medical conditions. 4, 6, 13, 27, 28 Elucidation of factors influencing mortality risk is important to inform clinical care and future interventions aimed at preventing premature death in HL survivors. To address these gaps in knowledge, we sought to 1) delineate cause-specific mortality in a cohort of pediatric HL survivors; 2) characterize the incidence and latency of key morbidities underlying mortality in survivors of childhood HL; and 3) investigate predictors of overall and leading cause-specific mortality.
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From
PATIENTS and METHODS

Characteristics of Study Participants
The CCSS is an ongoing multi-institutional study of individuals who survived > 5 years following treatment for childhood cancer. Subjects for this analysis met the following eligibility criteria: a) diagnosis of HL; b) diagnosis and initial treatment at one of 26 collaborating CCSS institutions; c) diagnosis date between January 1, 1970 and December 31, 1986; d) age younger than 21 years at diagnosis; and e) survival at least five years from diagnosis. A detailed description of the methodology and cohort characteristics has been reported previously. 29 The CCSS protocol and contact documents were reviewed and approved by the Human Subjects
Committee at each participating institution. Among the 2,742 eligible HL subjects, 1,927
(70.3%) enrolled survivors represent 13% of the CCSS respondent cohort. Figure 1 summarizes HL survivors eligible for mortality analysis, versus those enrolled in the cohort, and with available treatment data.
Data Sources and Definitions
The data sources for this CCSS analysis include: the U.S. National Death Index (NDI);
self-report questionnaires administered to the survivors or parent proxy; and treatment data for the initial HL, abstracted by the survivor's treating institution.
Mortality was evaluated among non-Canadian HL subjects eligible for CCSS as described previously. 27 The vital status and cause of death of all subjects eligible for CCSS was ascertained as of December 31, 2002, linking to the NDI, and followed up with a death certificate request from the state where the death occurred.
27,30
Eligible subjects (or a legal proxy for subjects who had died or were ≤18 years of age) who agreed to participate completed a baseline questionnaire at entry into the cohort. For traceable living subjects, follow-up questionnaires were collected at three subsequent times. Copies of all questionnaires and the treatment abstraction form are available for review at http://ccss.stjude.org. Questionnaire items specific to this analysis included: demographic information; cardiovascular (CV), pulmonary or thyroid conditions diagnosed by a physician; cancer recurrence; and development of a benign neoplasm, second malignant neoplasm (SMN) or non-melanoma skin cancer (NMSC). For medical conditions, subjects were asked to provide an age at first occurrence of the condition. Self-report of all SMNs was collected at each questionnaire and validated by pathology review of the report as previously described.
19,21
Histology for invasive SMNs was coded and classified with the use of the International Classification Diseases for Oncology (ICD-O). Recurrences are captured by participant selfreport and verified by review of medical records.
31
Chronic condition data were collected and scored based on baseline questionnaire response. Scoring of severity of chronic conditions was based on the Common Terminology Criteria for Adverse Events (version 3) system developed through the National Cancer Institute (http://ctep.cancer.gov). Conditions are graded as mild (grade 1), moderate (grade 2), severe (grade 3), life-threatening or disabling (grade 4), or fatal (grade 5) as previously described. 4 The current analysis utilized grade 3-5 CV conditions including: congestive heart failure requiring medication; myocardial infarction; angina or coronary heart disease on anti-angina medication, or requiring cardiac catheterization, angioplasty or coronary artery bypass graft surgery; heart transplantation; or cerebrovascular accident. Grade 3-5 pulmonary conditions included: emphysema on medication; pulmonary fibrosis on oxygen; pulmonary embolism and infarction. 4, 32 Thyroid chronic conditions included: thyroid nodules, hypothyroidism, or hyperthyroidism. 6, 33 For HL participants who signed a medical record release, a detailed summary of cancer treatment was abstracted by CCSS trained staff at the treating institution as previously described. exposure was divided into five categories by treatment field in reference to the diaphragm (supra-diaphragmatic, versus infra-or infra-plus supra-diaphragmatic) and dose (< 30 Gy, or > 30 Gy).
Statistical Analyses
The primary outcomes for this analysis were overall and cause-specific mortality.
Secondary outcomes included key chronic conditions, including SMNs. Descriptive statistics are presented by sex. To compare demographic and cancer treatment variables between genders,
Pearson chi-square tests were performed.
Follow-up time was defined as the interval from entry into the CCSS cohort (5 years after original cancer diagnosis) to the date of death from any cause, or censored at date of NDI search (12-31-2002) . Standardized mortality ratios (SMR) were calculated for overall and causespecific death in U.S. residents in the HL cohort ( Figure 1 ) and compared to the U.S. resident cohort. SMR was computed as the number of observed deaths divided by the expected number of deaths in an age, sex and calendar year matched general population, based on US mortality rates from the National Center for Health Statistics. A 95% confidence interval (CI) of each SMR was calculated based on Poisson probability models, and differences between groups were evaluated using likelihood ratio tests from these models.
35
Because the SMR only reflects the relative increase in risk, excess adverse risk (EAR)s were also calculated to illustrate the absolute increase in risk for a young population that has low
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From expected mortality rates. EAR per 10,000 person-years was determined by subtracting the expected number of events from the observed number, dividing the difference by total personyears of follow-up, and multiplying by 10,000. Cause of death was missing for 44 people; these were not included in cause-specific calculations. Estimated probabilities of overall survival were calculated by the method of Kaplan-Meier with associated 95% CI based on Greenwood's formula. Cumulative incidence and 95% CI were estimated for each cause-specific mortality, treating other causes of death as competing risks and conditioned on survival of 5, 10, 15 and 20 years since the original diagnosis.
36
The remaining analyses utilize questionnaire and treatment data from the respondent HL cohort (Figure1). Cumulative incidence and 95% CI were estimated for each of the following events: first recurrence of HL, histologically confirmed SMN, NMSC, grade 3-5 CV condition, grade 3-5 pulmonary condition, thyroid chronic conditions. Death was treated as a competing risk event and participants were censored at date of last questionnaire at which the outcome was ascertained. Events dated prior to cohort entry were included as prevalent at 5 years from diagnosis. All SMNs and recurrences reported up to and including the follow-up 2005
Questionnaire were included in this analysis. Excess risk of SMN (exclusive of NMSC) was evaluated using standardized incidence ratio (SIR) and EAR. SIR was calculated in a similar manner to that described above for SMR, utilizing U.S. Surveillance Epidemiology and End Results (SEER) age, sex and race-specific rates to calculate the expected number of cases.
19,37
All multiple SMNs were counted in the numerator of SIRs. EAR was determined as described above for mortality.
Cox proportional hazards regression, with age as the time scale, was used to assess the effects of demographics, cancer treatment, and medical conditions of interest (recurrence, SMN, CV event, NMSC, thyroid disease, pulmonary condition) on overall or cause-specific mortality and RT field were also tested in all mortality and SMN-mortality models. An interaction was found between sex and SMN in the overall mortality model; hence the final Cox model was stratified on sex to evaluate separate sex-specific effects of SMN. Due to the smaller number of cardiac deaths, a more parsimonious model (including sex, household income, and anthracycline score) was fit for CV mortality and a log rank test of RT was performed. Hazard ratios (HR), 95% CI, and p-values are reported.
Data were analyzed with SAS version 9.0 (SAS Institute, Cary, NC) and Tibco-Spotfire® S+ version 8.0 (Tibco Software Inc.), using 2-tailed statistical tests at the alpha = 0.05 level.
RESULTS
Characteristics of Childhood HL Survivors
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From Figure 1 delineates the HL survivors included in: mortality analysis, those enrolled in CCSS, and those with treatment data used for models to predict mortality. Among all 2,633 US HL survivors eligible for the analysis, 57% were male and 58% were treated from [1970] [1971] [1972] [1973] [1974] [1975] [1976] [1977] [1978] [1979] (Table1). Of the 1,927 HL survivors participating in CCSS, the median age at diagnosis was Treatment records available for 1,675 HL participants show 6% received chemotherapy alone for their initial HL treatment, while the rest received RT alone (33%) or combined with chemotherapy (61%). Chemotherapy included anthracyclines in 24% and alkylating agents in 56% of participants.
Mortality
Among 2,633 U.S. members of the eligible cohort, the 500 observed deaths are due to: HL (N= 175; 35%); SMN (N= 116; 23%); benign neoplasms (N= 4, <1%); cerebrovascular and heart disease (CV disease) (N=70; 14%); non-malignant respiratory disease (N=22; 4%); external cause (N=33; 7%); other (N=40; 8%); and unknown causes (N= 44; 9%) ( Table 2) . Estimates of cause-specific mortality and EAR for cause-specific mortality change when conditioned on time from initial diagnosis ( Figure 2b ; Table 2 ). Notably, the EAR of death from relapse decreases over the follow-up period, while the EAR from solid tumors, cerebrovascular disease and all heart disease increases over time.
Subsequent Neoplasms
Recurrent HL, SMN and non-invasive second neoplasms indicative of morbidity in 5-year HL survivors were delineated. The prevalence of recurrent HL was 8.1% (95% CI: 6.8-9.3) at cohort entry, with an increase to 11.9% (95% CI: 10.5-13.4) at 10 years and 15.0% (95% CI: Non-invasive neoplasms (NMSC; other benign neoplasms) also confer morbidity.
Cumulative incidence of NMSC at 30 years post diagnosis is 16.7% (95% CI 14.5, 19.4) ( Figure 3a ). Eighty two additional non-invasive neoplasms were reported, including non-infiltrating intraductal carcinoma of the breast (n=41), other breast histologies (n= 12) non-invasive meningioma (n= 2), neurilemmoma (n=3), noninvasive female genitourinary cancer (n=8), and other histologically unspecified neoplasms (n=16).
Chronic Medical Conditions
At least one chronic condition (grade 1-4) was reported by 70% (1348/1927) of survivors by baseline questionnaire response. Serious chronic conditions (grade 3-4) were enumerated in 27% (516/1927). Of these, 34% (174/516) were present at cohort entry, and 63% (327/516) were incident events after 5 years from diagnosis. Multiple morbidities were reported by HL survivors, with 44% having > 2 and 28% reporting > 3 chronic health conditions. The 30-year cumulative incidence of grade 3-5 CV conditions reported by the cohort is 11.1% (95% CI 8.5, 13.8) (Figure 3c ). There is no sex difference in incidence of reported CV conditions (log rank test, p=0.20). Specific CV conditions of concern among the 1,927 participants included: coronary artery disease requiring medication (2%, N=39); myocardial infarction (1.2%, N=24); congestive heart failure (1.5%, N=28); heart transplant for cardiomyopathy (0.1%, N=2); cerebrovascular accident (0.78%, N=15); and other (0.57%, N= 11).
The 30-year cumulative incidence of grade 3-5 pulmonary conditions or any thyroid conditions was 5.1% (95% CI: 3.3-6.9) and 51.1% (95% CI: 44.6-57.7), respectively ( Figure 3c ). Among these, 72% (38/53) of grade 3-5 pulmonary conditions and 52% (334/639) of thyroid conditions occurred after cohort entry. In evaluating leading morbidities driving overall mortality risk, there was a statistically significant interaction of sex with the type of SMN. Separation of effects of SMN type showed overall mortality was not associated with female breast cancer, but rather was associated with other SMN in both males and females (Table 4) . Finally, report of a grade 3-5 cardiac condition was also an independent risk factor for mortality (HR 4.4 [95% CI 2.7-7.3]). The occurrence of recurrent HL was evaluated in mortality models, and was neither significant nor was a confounder on treatment or key medical condition effect; hence recurrent HL was not included in final models.
Risks for Overall and Cause-Specific Mortality
A similar model for risk of death from SMN also showed independent associations of treatment with death ( 
cardiac deaths occurred in those who received > 30 Gy to any field. However, due to the small number of cardiac deaths, in a log rank test, RT was not significant (p= 0.81). Yet, non-breast SMNs in both men and women confers an excess independent risk for mortality after adjustment for treatment effects. Overall and SMN-specific mortality is associated with both RT and chemotherapy.
DISCUSSION
Importantly, 20 years after initial HL treatment, the excess death risk from CV disease rivals that from solid tumor SMN. The EAR for a CV mortality of 13.1 per 10,000 person-years is comparable to the estimate of 9.5 and 17.7 per 10,000 person-years in those treated at < 20 years age in the Dutch and Stanford cohorts, respectively, 25,39 and to the myocardial infarctionspecific mortality of 12.6 per 10,000 PY in a British cohort of both pediatric and adult HL survivors. 9 We noted an elevated incidence of congestive heart failure, coronary artery disease and cerebrovascular events in the cohort. The rates of fatal SMN in our cohort differ by Our regression model, adjusted for attained age, indicates no effect of age at treatment on overall, SMN, or CV specific mortality within a cohort treated during childhood. This does not negate prior findings in cohorts of combined pediatric and adult HL that noted increased mortality risk from SMN or CV disease in patients treated at < 21 years of age compared to those older at diagnosis. 25, 40 Following adjustment for key chronic medical conditions, initial cancer treatments (including RT exceeding 30 Gy, any anthracycline, or alkylating agent chemotherapy exposure) remain significant independent risks for overall and SMN-specific mortality. The lack of significance for anthracycline dose as a independent predictor of CV specific mortality in our cohort must be interpreted in the context of 94% of the CCSS cohort having received RT as initial therapy. 9 The effects of anthracycline and other chemotherapy (such as alkylating agents) will need to be distinguished from that of RT in childhood HL cohorts treated with contemporary approaches that minimize or avoid RT.
Sex affects multiple dimensions of health following childhood cancer therapy. 41 We show that male survivors of HL have a higher overall mortality compared to females, echoing previous single-institution and cohort studies with smaller event numbers among those treated in childhood. 23 41 Importantly, the reported incidence of grade 3-5 CV conditions in our cohort was not significantly higher in male survivors, yet their risk of mortality from CV disease was 3-fold that of their female counterparts. Possible explanations for our findings are that male survivors are twice as likely to receive no medical care. 42 An alternate explanation is that perception of CV risk or the symptom complex of CV events may differ between the sexes.
The steep rise in the cumulative incidence of serious CV conditions begins at 10 years after diagnosis, highlighting the temporal window for modifiable injury regardless of gender. 12, 39 Hence, investigation for biomarkers of subclinical CV injury and related interventions to preserve CV health should target this critical period. This is germane to HL which often presents in adolescence and necessitates transition from pediatric oncology to community primary medical care providers who may not be familiar with cancer-related health risks.
Our EAR estimates for breast cancer are consistent with the well-described elevated risk of breast cancer and its association with RT in female HL survivors. [16] [17] [18] 20, 28, 40 We now show that despite the high rates of non-invasive and invasive breast neoplasms, HL survivors with breast malignancies in the CCSS cohort have a comparable mortality risk to females with no history of SMN. Continued follow-up of this cohort will be important to evaluating this mortality effect over time. Although one could postulate that lower mortality is due to better surveillance and treatment options for breast cancer compared to the other second tumor types noted in the cohort, previous investigations have demonstrated suboptimal adherence to mammography screening recommendations in the CCSS cohort. 43 Alternately, an index invasive or non-invasive breast neoplasm may lead to better overall health surveillance for these women.
Our data support the current practice guidelines for heightened breast cancer surveillance, and The rates of NMSC and non-invasive breast neoplasms in HL survivors underscore the morbidity of these "low grade" entities, which often require multiple surgical procedures for surveillance and management. 47 While development of an NMSC within the RT field is a recognized risk, it portends increased tissue sensitivity to RT. Therefore, the decreased risk of overall mortality in cohort members who developed an NMSC was unexpected. Our finding could be explained by the fact that the occurrence of a NMSC serves as a gateway diagnosis for better overall health surveillance. Conversely, this population, who already has regular medical care, may be more likely to have an NMSC diagnosed. It is also possible that the mechanisms leading to RT-associated invasive or life threatening SMNs are independent from those for development of an NMSC.
While the CCSS cohort of 5-year survivors of HL is rich in treatment and co-morbidity data, results must be interpreted in light of limitations of its unique retrospective-prospective design. The current analysis utilized a mixture of well-validated variables (death, SMN, treatment, RT dose and field), and variables based on self-report, which have not been fully adjudicated (pulmonary, CV condition). In addition, multivariable models constructed on information from the 87% of the cohort with full available treatment data may reflect participants with more serious illness. However, the Nordic cohort comparable to the CCSS treatment era, with 94% follow-up of all survivors and outcomes verified by physician exam, reported chronic illness rates similar to that of the CCSS. 48 Lastly, risks derived primarily from rare events that Regardless, the CCSS remains the largest available cohort with the most extended follow-up, making it a rich resource for understanding childhood cancer survivors' long-term outcomes. The expanded CCSS cohort, currently being assembled will have the ability to evaluate HL survivors treated with contemporary chemotherapy only and combined modality approaches, as it encompasses children treated from 1987-1999. While it is anticipated that more targeted contemporary approaches (i.e. risk-and response-based chemotherapy, immunotherapy;
anti-angiogenic agents, involved and targeted nodal RT) will minimize the incidence of SMN and CV disease in the next generation of survivors, decades of follow up will be required to document the magnitude of impact of such approaches delivered to the growing child. The strong association of RT with SMN, and CV morbidity and mortality substantiates current and future cooperative group strategies to minimize and obviate the use of RT while maintaining disease free survival in the treatment of childhood HL. However, given the radiosensitivity of HL, it remains that some proportion of patients will ultimately require RT to optimize disease control.
In summary, HL survivors continue to be at risk for treatment-related mortality for decades beyond their initial disease. SMN and CV conditions represent the leading morbidities underlying the risk of premature death; sex and specific treatment modality influence this risk.
HL survivors and clinicians supervising their medical care should be vigilant for these genderand therapy-specific health risks. Research is needed to evaluate if health surveillance programs that facilitate early diagnosis of cancer-related morbidity can optimize long-term health outcomes in childhood cancer survivors. 
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